Daybue (trofinetide) prior authorization
Customize your policy alerts
Sign up for all Colorado Rocky Mountain Health Plans policy alerts
Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization and reauthorization requirements for Daybue (trofinetide) for treatment of Rett syndrome in members of Colorado Rocky Mountain Health Plans; applies to providers requesting coverage for this medication.
No material clinical or coverage changes in this revision.
Coverage Criteria for Daybue (trofinetide)
Initial Authorization
Covered when ALL of the following are met
Authorization issued for 12 months
Reauthorization
Covered when ALL of the following are met
Authorization issued for 12 months
Coverage for Daybue (trofinetide) is subject to both regulatory requirements and the member’s specific benefit plan. State mandates, any applicable federal regulatory requirements, and the details of the member’s benefit plan may affect whether services meet these coverage criteria. Other internal policies and utilization management programs may also apply and could influence authorization decisions.
Initial Therapy
Initial Therapy
Initial approval criteria
Authorization issued for 12 months
Continuation / Reauthorization Criteria
Reauthorization
Reauthorization requirement
Authorization issued for 12 months
Provider Actions and Authorization Notes
Prior authorization required for initial therapy; 12‑month authorization
Prior authorization is required for Daybue. For initial requests, submit documentation showing (1) a diagnosis of Rett syndrome (RTT) AND (2) the patient is at least 2 years of age. Authorizations are issued for 12 months.
- Initial approval requires both: diagnosis of Rett Syndrome and patient age ≥2 years
- Authorization duration: 12 months
Automated approval permitted per program rules
Automated approvals or approvals based solely on prior claim/medication history and diagnosis codes (ICD-10) may be used according to program rules; use of automated approval/re-approval processes varies by program or therapeutic class.
- Programs may approve initial and reauthorization requests based on previous claim/medication history, diagnosis codes, and/or claim logic
- Use of automated approval and re-approval processes varies by program and therapeutic class
Reauthorization requires documented positive clinical response
For reauthorization, submit documentation demonstrating a positive clinical response to Daybue therapy. Reauthorizations are issued for 12 months.
- Documentation must specifically indicate positive clinical response to Daybue
- Authorization duration for reauthorization: 12 months
Denial triggers: missing RTT diagnosis or age under 2 years
Requests lacking a diagnosis of Rett syndrome or for patients younger than 2 years may be denied for not meeting eligibility criteria.
- No Rett syndrome diagnosis = potential denial
- Patient age <2 years = potential denial
Definitions
Background
Daybue (trofinetide) is a synthetic analog of the amino‑terminal tripeptide of insulin‑like growth factor‑1 (IGF‑1) indicated for the treatment of Rett syndrome in patients aged 2 years and older. The policy defines criteria for initiation and continuation of Daybue, including requirements for documented diagnosis and evidence of clinical response; when met, authorizations are issued for 12 months.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.